Mosaic ImmunoEngineering Inc. (CPMV) Stock
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Mosaic ImmunoEngineering Inc. is headquartered in US.
Mosaic ImmunoEngineering Inc. (CPMV) stock trades at $0.55 with a market capitalization of $3.98M. The stock is valued at a price-to-earnings (P/E) ratio of -6.11, price-to-book of -0.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.31 and $1.05, and currently trades 47.6% below its 52-week high.
On profitability, Mosaic ImmunoEngineering Inc. generates a return on equity (ROE) of 9.22%, return on capital employed of 9.67%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.mosaicie.com